Jumar Mentoring Program
The Jumar Mentoring Program offers both Peer Mentors and Consultant Mentors, giving Jumar biotech startups access to targeted, practical advice at critical stages of their journey.
Each mentor commits to providing an in-kind 1-hour session to address a specific technical, commercial, or strategic question, from clinical development and regulatory strategy through to manufacturing, partnering, and scale-up. This program is open to all (C-suite, L-suite, Team Member).
To request a warm introduction, please fill out this mentor form. If there isn’t a mentor who matches your specific need, we’ll reach out to our broader network to find the right person for you.
Please see curated list of our select mentors below.
|
|
Medical Oncologist and Chief Medical Officer, Nucleus Network |
Phase 1 first-in-human oncology trials, clinical pharmacology, early clinical development, global trial operations, US–Australia clinical strategy |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gerhard Rank |
|
Biologics and vaccine development, scale-up and manufacturing with CDMOs, outsourced development partnerships, operational and technical challenges |
Thomas Ulmer |
CFO, COO, CEO, Cell Therapies Pty Limited |
General management and finance |
Steven Rockman |
External Innovation, CSL (20 years with CSL) |
Vaccines |
Anand Gautam |
Founder, G2OME Consulting Pty Ltd; Former Head of APAC Emerging Science & Innovation, Global R&D, Pfizer |
R&D strategy, translation, and commercialisation |
Rachelle Kirk-Burnnand |
CRA; Project Manager (CRO); Global PM (USA, Europe, APAC); Director Clinical Operations |
Clinical operations, trial delivery, vendor procurement |
Helen Poliviou |
Founder and Managing Director, PureCDM |
Early-phase clinical development, Phase 1 strategy, protocol and dose-escalation design, trial execution, translational planning, global development |
Michael Fitzgerald |
Director Biostatistics APAC, PureCDM |
Clinical trial strategy, biostatistics, data analysis and problem solving |
Michelle Papadimitriou |
Research and Commercialisation Associate; R&D Project Manager |
Early- to mid-stage drug development, management of pre-clinical, non-clinical, and CMC contracts |
James Posnett |
General Manager, Listings at the Australian Securities Exchange (ASX) |
Capital markets in Australia and internationally |
Grant Lester |
Over 10 years as Executive Director at Social Research Centre. As a coach, 8 years. |
Leadership, management, operations, business operations, coaching, high-performance, people management, culture, building teams, scaling, driving engagement, delivering results, reporting, strategy and recruitment. |
Joanne Hilderbrand |
Medical Science Liaison, Eli Lilly, Cardiometabolic Health |
Cell Biology and preclinical models of disease, navigating academia, career moves to industry |
Jeremy Gale |
30 years + ex-Pfizer, ex-GSK, Biopharma Executive and Clinical Drug Development Consultant |
Clinical stage drug development (pre-FIH through Phase 2) including translational research |
Guillaume Lessene |
Associate Director Therapeutic Discovery, WEHI; Cofounder exteRNA; CSO Anaxis Pharma |
Accomplished leader with more than 20-years’ experience in the biomedical research and translation sector |
Andrew Kelly |
Executive Director and Co-Founder of BioPacific Partners |
35 years of experience spanning science, commercialisation, and investment across pharma, food, agriculture, and health. Leds international R&D at major research institutes in Australia and New Zealand, working closely with emerging ventures and funding pathways |
Perdita Cheshire |
Senior Director, Early Partnerships & Transactions Lead, CSL |
Experienced life sciences leader specialising in research strategy, external innovation, and global partnering. She has a strong background in early-stage partnering, with prior experience in biotechnology business development and advisory. |